Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAG)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This is a Phase III, double‐blind, randomised study assessing the efficacy and safety of Alflutinib Mesylate (AST2818) (80 mg orally, once daily) versus Gefitinib (250 mg orally, once daily] in patients with locally advanced or metastatic Non‐small Cell Lung Cancer (NSCLC) that is known to be EGFR sensitising mutation (EGFRm) positive for first‐line treatment with an EGFR‐TKI.
Epistemonikos ID: 621a2d8e474545b7ceda33a75fe8b9d3df92802d
First added on: May 21, 2024